<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mov Disord Clin Pract</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov Disord Clin Pract</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2330-1619</journal-id>
<journal-id journal-id-type="publisher-id">MDC3</journal-id>
<journal-title-group>
<journal-title>Movement Disorders Clinical Practice</journal-title>
</journal-title-group>
<issn pub-type="epub">2330-1619</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30838254</article-id>
<article-id pub-id-type="pmc">6353388</article-id>
<article-id pub-id-type="doi">10.1002/mdc3.12328</article-id>
<article-id pub-id-type="publisher-id">MDC312328</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Case Report</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel Nonsense Calmodulin‐Binding Transcription Activator 1 Mutation Presenting as a Tremor‐Predominant Phenotype</article-title>
<alt-title alt-title-type="left-running-head">S. Agarwal et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="mdc312328-cr-0001">
<name>
<surname>Agarwal</surname>
<given-names>Shashank</given-names>
</name>
<degrees>MD</degrees>
<address>
<email>shashank.agarwal@nyumc.org</email>
</address>
<xref ref-type="aff" rid="mdc312328-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mdc312328-cr-0002">
<name>
<surname>Gilbert</surname>
<given-names>Rebecca</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="mdc312328-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mdc312328-cr-0003">
<name>
<surname>Lau</surname>
<given-names>Heather A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="mdc312328-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="mdc312328-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>New York University School of Medicine</institution>
<named-content content-type="city">New York</named-content>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff>
<aff id="mdc312328-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Neurogenetics</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>New York University School of Medicine</institution>
<named-content content-type="city">New York</named-content>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence to</bold>: Dr. Shashank Agarwal, The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, Department of Neurology, NYU Langone Medical Center, 240 East 38th Street, 20th Floor, New York, NY 10016; E‐mail: <email>shashank.agarwal@nyumc.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<season>Nov-Dec</season>
<year>2016</year>
</pub-date>
<volume>3</volume>
<issue>6</issue>
<issue-id pub-id-type="doi">10.1002/mdc3.2016.3.issue-6</issue-id>
<fpage>611</fpage>
<lpage>614</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 International Parkinson and Movement Disorder Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 International Parkinson and Movement Disorder Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:MDC3-3-611.pdf" xlink:type="simple"></self-uri>
<abstract id="mdc312328-abs-0001">
<title>Abstract</title>
<p>A 25‐year‐old right‐handed male presented with head and bilateral arm and leg tremor. His symptoms began at age 10 years with action tremor of both hands and progressed in severity with time. He had difficulty with social interactions but did not have intellectual disabilities. His past medical history was significant for obsessive compulsive disorder and anxiety, asthma, gastroesophageal reflux disease, and scoliosis; and his family history was significant for tremor in his father and paternal grandfather. Genetic testing was performed and identified a deleterious sequence variation in exon 19 of the calmodulin‐binding transcription activator 1 (<italic><styled-content style="fixed-case">CAMTA</styled-content>1</italic>) gene. The presence of this sequence variation was confirmed in the patient and in his affected father. The case is novel because of tremor predominance and because the mutation is a sequence variation rather than a deletion or duplication.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="mdc312328-kwd-0001">calmodulin‐binding transcription activator 1 (<italic><styled-content style="fixed-case">CAMTA</styled-content>1</italic>) mutation</kwd>
<kwd id="mdc312328-kwd-0002">essential tremor</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<page-count count="4"></page-count>
<word-count count="1741"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>mdc312328</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>November/December 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.6 mode:remove_FC converted:17.01.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group id="mdc312328-ntgp-0001">
<fn id="mdc312328-note-0001">
<p>Supporting information may be found in the online version of this article.</p>
</fn>
<fn id="mdc312328-note-0002">
<p>Relevant disclosures and conflicts of interest are listed at the end of this article.</p>
</fn>
</fn-group>
</notes>
</front>
</article>
</pmc-articleset>